Cargando…
Time to switch from CLSI to EUCAST? A Southeast Asian perspective
Autores principales: | Cusack, T.P., Ashley, E.A., Ling, C.L., Roberts, T., Turner, P., Wangrangsimakul, T., Dance, D.A.B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587905/ https://www.ncbi.nlm.nih.gov/pubmed/30922928 http://dx.doi.org/10.1016/j.cmi.2019.03.016 |
Ejemplares similares
-
Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019) -
Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023) -
Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms
por: Wolfensberger, Aline, et al.
Publicado: (2013) -
Molecular Identification and Antifungal Susceptibility Patterns of Clinical Dermatophytes Following CLSI and EUCAST Guidelines
por: Dabas, Yubhisha, et al.
Publicado: (2017) -
1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)